Loading clinical trials...

Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation | Clinical Trials | Clareo Health

COMPLETED

Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation

A Non-interventional, Single-visit Study Focusing on the Evaluation of Glistening as Well as General Safety and Visual Outcomes With at Least 24 Months Follow-up in Patients Implanted With CT LUCIA 621P Intraocular Lenses

NCT07297719•Carl Zeiss Meditec AG

View on ClinicalTrials.gov

Summary

Main evaluation of glistening at least 24 Months post-IOL implantation

Detailed Description

Evaluation of glistening, visual outcomes and general safety after at least 24 Months post-IOL implantation

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients currently implanted with the CT LUCIA 621P IOL into the capsular bag in at least one eye and who participated in previous study "CT LUCIA 621P-BER-401-21";
•2. A minimum follow-up period of 24 months after the IOL implantation of the study eye (selected as the study eye in the previous study);
•3. Patients willing and capable of providing informed consent;
•4. Patients willing and capable of complying with visits and procedures as defined by this protocol.

Exclusion Criteria

•1. Complications during cataract surgery with clinically significant impact;
•2. Postoperative clinically significant corneal or retinal pathology as well as postoperative acute or chronic inflammatory ocular conditions (e.g. uveitis, iritis etc.);
•3. Presence of clinically significant PCO with potential to limit the glistening evaluation;
•4. IOL dislocation (the complete IOL is not stable fixated in the capsular bag);
•5. Patients unable to meet the limitations of the protocol or likely of non-cooperation during the clinical investigation;
•6. Patients whose freedom is impaired by administrative or legal order.

Locations (1)

Aier Eye Hospital of BoAo Hope City

Hainan, Hainan, China

Key Dates

Start Date

December 25, 2025

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2025

Last Updated

January 16, 2026

Enrollment

ACTUAL participants

Conditions

Cataract Senile

Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement

NCT04570579

CataractCataract Senile+1 more

View study

COMPLETEDNA

Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction

NCT06483750

Dry Eye DiseaseMeibomian Gland Dysfunction+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation

Inclusion Criteria

Exclusion Criteria

Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement

Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction

Accuracy of Topography Guided Automatic Marking of the Intraocular Lens (IOL) -Axis

The Effect of LASIK on the Calibration of IOL Formula Calculation: a Comparative Study

Ocular Coherence Tomography During Cataract Assessment

VISPER: Randomised Comparison of Two OVDs in Cataract Surgery